ValiRx plc

LSE (GBp): ValiRx plc (VAL)

Last Price

0.675

Today's Change

+0.125 (22.72%)

Day's Change

0.60 - 0.875

Trading Volume

40,577,446

Profile
VAL

Exchange:  London Stock Exchange London Stock Exchange

Currency:  GBp GBp

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Mark Eccleston M.B.A., Ph.D. Dr. Mark Eccleston M.B.A., Ph.D.

Full Time Employees:  16 16

IPO Date:  2002-01-07 2002-01-07

CIK: 

ISIN:  GB00BLH13C52 GB00BLH13C52

CUSIP:  G9313Z140 G9313Z140

Beta:  -0.47 -0.47

Last Dividend:  0.00 0.00

Dcf Diff:  0.53 0.53

Dcf:  0.26 0.26

Description

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

Address

Stonebridge House,
Hatfield, CM22 7BD, GB

442030084416

http://www.valirx.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment